Archive for September 11th, 2009
Title: Radiculopathy
Category: Diseases and Conditions
Created: 9/10/2009 2:49:00 PM
Last Editorial Review: 9/10/2009 2:49:31 PM
Research published today in the New England Journal of Medicine has described how progressive multifocal leukoencephalopathy (PML) infection may occur in people taking Tysabri, a drug licensed for use in relapsing remitting multiple sclerosis (MS). PML is a serious and often fatal infection of the brain that is estimated to occur in approximately one in 1,000 people taking Tysabri over the course of 18 months.
The virus responsible for PML (progressive multifocal leukoencephalopathy), a rare brain disease that typically affects AIDS patients and other individuals with compromised immune systems, has been found to be reactivated in multiple-sclerosis patients being treated with natalizumab (Tysabri). The findings, led by scientists at Beth Israel Deaconess Medical Center (BIDMC), appear in The New England Journal of Medicine (NEJM).
Being resilient isn’t easy. But with the right attitude, you’ll do well.
ABOUT
Your online resource center for Multiple Sclerosis Information
RECENT POSTS
Best Selling Book
Subscriptions
RSSContributors
Archives
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008